The National Library of Medicine has stopped indexing articles from Scientific Reports in MEDLINE because the journal’s inclusion in the world’s largest biomedical library is under review, Retraction Watch has learned.
“Following its significant growth in recent years, Scientific Reports is currently being reviewed by the US National Library of Medicine (NLM),” the journal’s chief editor Rafal Marszalek wrote in an Oct. 20 email we have seen. “We have been informed that during this period, indexing of newly published content in MEDLINE and archiving in PubMed Central (PMC) are paused, and will not appear in PubMed.”
Marszalek did not say why NLM is reviewing Scientific Reports, which is the largest journal in PubMed in terms of articles indexed. But according to MEDLINE’s policies page, NLM re-evaluates journals if “there are significant changes to a journal,” noting the library monitors journals “for changes in publication practices, such as annual publication volume or primary article content types.”
The most recent Scientific Reports articles in PubMed were published September 15, and it has indexed 28,593 articles in 2026, excluding errata and retraction notices. According to the journal’s website, it has published 41,122 articles this year.
Scientific Reports “has grown significantly since its launch 15 years ago when it was also first indexed by National Library of Medicine (NLM),” Richard White, vice president of publishing for the Scientific Reports Portfolio, said in a statement to Retraction Watch. “It has published over one million authors and in 2025 research from the journal was cited over one million times. We remain committed to maintaining high standards of quality and are actively working with the NLM to provide any updated information they need.”
The anomaly was discovered by Tom Lahey, a self-described “independent, self-funded researcher with an interest in public health and research.” Lahey maintains a set of tools based on PubMed data, including a page showing journals ranked by total articles in PubMed. Scientific Reports has had the most articles indexed in PubMed each year since 2019, by Lahey’s count. He is familiar with the typical delays in data processing, but when he noticed lower-than-usual numbers for Scientific Reports for two months in a row, he opened a support ticket with NLM to inquire why. The PubMed team suggested he contact the publisher, which he did. Marszalek replied to him on October 20 revealing NLM was reviewing the journal.
“Something really must have gone sideways,” Lahey told Retraction Watch.
Neither the journal’s NLM catalog entry nor its PubMed Central listing indicate the journal is under review. NLM did not immediately respond to questions about the reasons for the review or how long it is expected to take, or whether the list of journals being reevaluated is made public. But the policy page states reevaluation typically takes seven to 10 months.
“We are in contact with NLM, and we expect that indexing, including of content published during the current period, will resume following the review,” Marszalek said in the email.
Scientific Reports, published by Springer Nature, has around 50 full-time deputy, senior and associate editors, and more than 11,000 editorial board members. Its article processing charge is $2850.
Like Retraction Watch? You can make a tax-deductible contribution to support our work, follow us on X or Bluesky, like us on Facebook, follow us on LinkedIn, add us to your RSS reader, or subscribe to our daily digest. If you find a retraction that’s not in our database, you can let us know here. For comments or feedback, email us at [email protected].

“We remain committed to maintaining high standards of quality….”
Did he say that with a straight face?
Well said. I’ve been in disbelief for a while at the quality at SR.
If you say it often enough you will ultimately believe your own lies.
By and large, Scientific Reports is a repository for articles that were submitted to (and subsequently rejected by) Nature and Nature sub-journals. The rejection letters all come with an offer to be considered by SR and ultimately published if you’re willing to pay their article processing fee. Its similar to AC$’s ACS Omega journal — “your paper wasn’t good enough for our primary journals, but we’ll publish it if you’re willing to pay!”
I’ve used it when I had pet research projects that didn’t really fit anywhere else, detecting THC on surfaces after cleaning, cannabis use trajectories over time, stuff like that. The science is solid but the topic is either unpopular or the results are unexpected and may not be reproducible. It’s not a journal of last resort but it’s not a CV stain either.
With scientifically sound article titles such as magic electron affection and Mona Lisa is always happy And only sometimes sad, it’s a wonder it’s taken this long to raise a red flag
The root cause here is not the journal. All journals want to survive by maximizing profits while they can. No one can stop them due to the following fact. Now, which entities (universities, research institutions…) hire, and which agency pay these researchers to publish mediocre results faster? SR and other journals should allocate more of their profits from these researchers to improve AI-assisted human peer-reviews and willing to publish high-quality work (after proper verification) of genuine and honest researchers who really have no funding and who do not use AI at all. You can’t eliminate the problem, but at least you can bring some balance.
Como não usar IA? Essa ferramenta se tornou essencial para otimizar e fazer cruzamento de dados, se usada com cuidado e sabedoria.
>All journals want to survive by maximizing profits while they can.
I am old enough to remember a time when most highly regarded journals were run on a nonprofit basis by the relevant scientific society.
With these numbers the annual revenue to the publisher from this journal alone is over $100M. That is money taken out of scientific research.
To be exact last year it was 45907×2850 = 130 834 950 USD.
Can’t say I’m surprised! They’ve been behaving like a predatory journal for quite some time now.
My personal experience: last year they published a paper on COVID-19 deaths with blatant errors and inconsistencies (https://www.nature.com/articles/s41598-025-98834-y), we pointed those out in a letter with full documentation and analysis code on GitHub (https://zenodo.org/records/16922988), and they didn’t even care to publish it, offering the lamest of excuses…
This situation deserves transparency and timely clarification from Springer Nature and the NLM. A temporary indexing pause does not necessarily mean delisting, but authors deserve clear information about the review process and how publications during this period will be handled. Protecting researchers’ interests and maintaining trust in scientific publishing should be priorities.
Corp-speak (can it possibly be generated rather than written?) is less than appreciated. As is said, having an article in a journal is a privilege, not a right. “Interests of researchers,” whatever that means, should never take precedence over keeping the scientific record rigorous.
Scientific report do thorough review by sending to several reviewers and passing through several rounds. Many other journals that keeps rejecting are playing hard and publishing for only their contacts and researcher friends. Check those journals, they also have alot of AI generated and low quality research works
Sure, this must have undergone rigorous review:
“Adjust the data and parameters as needed for your specific use case. […] These values are illustrative and should be replaced with actual experimental results or data from credible research when conducting a real comparative analysis.”
https://pubpeer.com/publications/41360C82D18678BE949910962DCE16
Or this one:
https://pubpeer.com/publications/FCC69CBDD5265C1B12A7C10533D90D
No action after more than 9 months.
Not suprised! this revelation is long overdue
They published a meta-analysis of mortality with statins in HIV that was based of a blatant misunderstanding of statistics (https://www.nature.com/articles/s41598-022-23102-2) but refused to take any action despite multiple emails pointing out the mistake.
in my group, since its inception, ST was regarded as a place to publish the leftovers, just pay and tey publish. never trusted any single paper coming from there.
I have reviewed 4 articles for Scientific Reports in the last year. All were of poor quality and almost certainly AI generated. Fortunately, all were rejected by the journal.
For NLM MEDLINE to actually place a journal on hold is no small accomplishment. Not even the predatory publishers operating from the more entrepreneurial corners of India have managed to earn that particular distinction.
My experience. I published there lately. One of the authors was deceased and Springer is one of the few publishers (at least among those I know) that don’t request deceased authors to be in the acknowledgent section. What can I say: in my case the review process was real and improved the manuscript. The editorial workflow, on the other side, was vey unprofessional. It took more than 1 year to have the article published, and that happened after repeated requests and reminders. The Editor in chief cannot be reached, there isn’t even an email address. The editorial office is not helpful (but this Is a situation common to many other journals from other publishers)
Correspondents have pointed out that these fakes are of poor quality and easy to catch after publication by cursory examination. There is often a need for fake science in non-traditional careers. This illustrates the need for instructing scientists in [certain countries] in improving their faking skills. I would propose that faking take its place as an accepted technique for serious study. Faking appears in more scientific papers than traditional techniques such as even PCR.
I propose a new open source journal devoted to faking research, *Ambivalent Science*. Submissions may be sent with a $550 editing and processing fee. We will initiate the first edition with a conference at [country to be determined]. The proposed keynote speaker will be Robert F. Kennedy Jr. [invited]. Other proposed speakers will be Joseph A. Ladapo [invited] and Andrew Wakefield [invited]. The theme of this conference will be, “The Use of Ambivalent Science in Regulatory Approval and Marketing of Ethical and Non-Ethical Dietary Supplements.” There will be workshops on topics like statistics, preparing a scientific paper and press release, and “How to write the perfect abstract”. Attendance at the conference will be $350, which includes a 250-word abstract in the conference proceedings.
Tagline of my next talk: Figures don’t Lie but Liars can Figure: How to Mislead a Scientifically Illiterate Audience
approx $130 million in revenue last year! but reviewers still dont get paid by these journals.
The figure I see for 2024 as originally stated is £3.051 billion revenue with an operating profit of £1.172 billion for RELX/STM, which only slightly overstates Elsevier’s contribution to the conglomerate. In 2026 the 2024 figures were restated as £2.624 billion, adjusted operating profit of £981 million.
https://publishingstate.com/how-much-profit-did-elsevier-make-in-2024/2025/